Globotriaosylsphingosine actions on human glomerular podocytes: Implications for Fabry nephropathy

Nephrology Dialysis Transplantation

Volumn 26, Issue 6, 2011, Pages 1797-1802

  Sanchez Niño, Maria D ^a   Sanz, Ana B ^b   Carrasco, Susana ^a   Saleem, Moin A ^c   Mathieson, Peter W ^c   Valdivielso, Jos M ^d   Ruiz Ortega, Marta ^a   Egido, Jesus ^a   Ortiz, Alberto ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d UNIVERSITY OF LLEIDA   (Spain)

Author keywords

fabry disease; glomerular injury; podocytes

Indexed keywords

CD74 ANTIGEN; COLLAGEN TYPE 4; FIBRONECTIN; GLOBOTRIAOSYLCERAMIDE; GLOBOTRIAOSYLSPHINGOSINE; PARICALCITOL; SCLEROPROTEIN; SPHINGOSINE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

ARTICLE; CONTROLLED STUDY; ENZYME SUBSTRATE; EXTRACELLULAR MATRIX; FABRY DISEASE; GENE ACTIVATION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; PODOCYTE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RENAL PROTECTION;

ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; BLOTTING, WESTERN; CELLS, CULTURED; EXTRACELLULAR MATRIX PROTEINS; FABRY DISEASE; GLYCOLIPIDS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; KIDNEY GLOMERULUS; PODOCYTES; RECEPTORS, CALCITRIOL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SPHINGOLIPIDS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 79958165587     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq306     Document Type: Article

References (35)

1. Brady RO, Gal AE, Bradley RM et al. Enzymatic defect in Fabry's disease ceramidetrihexosidase deficiency. N Engl J Med 1967; 276: 1163-1167.
2. Kint JA. Fabry's disease: alpha-galactosidase deficiency. Science 1970; 167: 1268-1269.
3. Askari H, Kaneski CR, Semino-Mora C et al. Cellular and tissue localization of globotriaosylceramide in Fabry disease. Virchows Arch 2007; 451: 823-834. (Pubitemid 47497940)
4. Ortiz A, Oliveira JP, Wanner C et al. Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults. Nat Clin Pract Nephrol 2008; 4: 327-336. (Pubitemid 351769331)
5. Waldek S, Patel MR, Banikazemi M et al. Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med 2009; 11: 790-796.
6. Alroy J, Sabnis S, Kopp JB. Renal pathology in Fabry disease. J Am Soc Nephrol 2002; 13: S134-S138. (Pubitemid 34579224)
7. Fogo AB, Bostad L, Svarstad E et al. Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). Nephrol Dial Transplant 2010; 25: 2168-2177.
8. Ortiz A, Oliveira JP, Waldek S et al. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant 2008; 23: 1600-1607. (Pubitemid 351767751)
9. Ortiz A, Cianciaruso B, Cizmarik M et al. End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry. Nephrol Dial Transplant 2010; 25: 769-775.
10. Branton MH, Schiffmann R, Sabnis SG et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 2002; 81: 122-138. (Pubitemid 34218568)
11. Mora C, Navarro JF. Inflammation and diabetic nephropathy. Curr Diab Rep 2006; 6: 463-468. (Pubitemid 44896406)
12. Germain DP, Waldek S, Banikazemi M et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 2007; 18: 1547-1557. (Pubitemid 46717522)
13. Torra R. Renal manifestations in Fabry disease and therapeutic options. Kidney Int Suppl 2008; 111: S29-S32.
14. Tahir H, Jackson LL, Warnock DG. Antiproteinuric therapy and Fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. J Am Soc Nephrol 2007; 18: 2609-2617. (Pubitemid 47378878)
15. Agarwal R, Acharya M, Tian J et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005; 68: 2823-2828. (Pubitemid 43251029)
16. Lambers Heerspink HJ, Agarwal R, Coyne DW et al. The selective vitamin D receptor activator for albuminuria lowering (VITAL) study: study design and baseline characteristics. Am J Nephrol 2009; 30: 280-286.
17. Aerts JM, Groener JE, Kuiper S et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA 2008; 105: 2812-2817. (Pubitemid 351723626)
18. Moreno JA, Sanchez-Nino MD, Sanz AB et al. A slit in podocyte death. Curr Med Chem 2008; 15: 1645-1654.
19. Ziyadeh FN. Mediators of diabetic renal disease: the case for TGFbeta as the major mediator. J Am Soc Nephrol 2004; 15: S55-S57. (Pubitemid 38018457)
20. Sanchez-Nino MD, Sanz AB, Ihalmo P et al. The MIF receptor CD74 in diabetic podocyte injury. J Am Soc Nephrol 2009; 20: 353-362.
21. Saleem MA, O'Hare MJ, Reiser J et al. A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol 2002; 13: 630-638. (Pubitemid 34183927)
22. Carvajal G, Rodriguez-Vita J, Rodrigues-Diez R et al. Angiotensin II activates the Smad pathway during epithelial mesenchymal transdifferentiation. Kidney Int 2008; 74: 585-595.
23. Cardus A, Panizo S, Parisi E et al. Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res 2007; 22: 860-866. (Pubitemid 351339746)
24. Ruiz-Ortega M, Ruperez M, Esteban V et al. Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol Dial Transplant 2006; 21: 16-20. (Pubitemid 43057101)
25. Iglesias de la CruzMC, Ziyadeh FN, IsonoMet al. Effects of high glucose andTGF-beta1 on the expression of collagen IVand vascular endothelial growth factor inmouse podocytes. Kidney Int 2002; 62: 901-913. (Pubitemid 35316719)
26. Mori Y, Ishida W, Bhattacharyya S et al. Selective inhibition of activin receptor-like kinase 5 signaling blocks profibrotic transforming growth factor beta responses in skin fibroblasts. Arthritis Rheum 2004; 50: 4008-4021. (Pubitemid 39643950)
27. Yamauchi K, Takano Y, Kasai A et al. Screening and identification of substances that regulate nephrin gene expression using engineered reporter podocytes. Kidney Int 2006; 70: 892-900. (Pubitemid 44285966)
28. Wiggins RC. The spectrum of podocytopathies: a unifying view of glomerular diseases. Kidney Int 2007; 71: 1205-1214. (Pubitemid 46884251)
29. Park IS, Kiyomoto H, Abboud SL et al. Expression of transforming growth factor-beta and type IV collagen in early streptozotocininduced diabetes. Diabetes 1997; 46: 473-480. (Pubitemid 27090278)
30. Sharma K, Ziyadeh FN, Alzahabi B et al. Increased renal production of transforming growth factor-beta1 in patients with type II diabetes. Diabetes 1997; 46: 854-859. (Pubitemid 27188264)
31. Pantsulaia T. Role of TGF-beta in pathogenesis of diabetic nephropathy. Georgian Med News 2006; 131: 13-18.
32. Alsaad KO, Herzenberg AM. Distinguishing diabetic nephropathy from other causes of glomerulosclerosis: an update. J Clin Pathol 2007; 60: 18-26. (Pubitemid 46142667)
33. Mason RM, Wahab NA. Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol 2003; 14: 1358-1373. (Pubitemid 36519197)
34. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD WorkGroup.KDIGOclinical practice guideline for the diagnosis, evaluation, prevention, and treatment ofChronic KidneyDisease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; 113: S1-S130.
35. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: S1-S201